1	Brief Research Report (Short Communication)
2 3	Biological and Disease Hallmarks of Alzheimer's Disease Defined by Alzheimer's Disease Genes
4 5	Shin Murakami* and Patricia Lacayo
6	
7 8	Department of Basic Sciences, College of Osteopathic Medicine, Touro University California, Vallejo, CA 94592.
9 10 11	*, Corresponding author, Shin Murakami, PHD, FGSA
12 13	Abstract
14 15 16 17 18 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 9 40 41 42	An increasing number of genes associated with Alzheimer's disease (AD) have been reported. However, despite previous studies, there is a lack of overview of the genetic relationship between AD and age-related comorbidities, such as hypertension, myocardial infarction, and diabetes, among others. Previously, we used Reactome analysis in conjunction with the genes that are associated with AD (AD genes) to identify both the biological pathways and the neurological diseases involved. Here we provide systematic updates on the genetic and disease hallmarks defined by AD genes. There are a total of 11 pathways (defined as genetic biological hallmarks) including 6 existing hallmarks and 5 newly updated hallmarks, the latter of which are developmental biology (axon and adipose development), gene expression (RNA transcription), metabolism of proteins (Amyloid formation, regulation of IGF-1/Insulin, and small ubiquitin-like modifiers/SUMOs), metabolism of RNA (mitochondrial tRNA and rRNA processing), and signal transduction (ErbB, NOTCH and p75 NTR death signaling). The AD genes further identified 20 diverse diseases that we define as disease hallmarks including: (1) existing hallmarks, including neurological diseases (Alzheimer's disease, Amyotrophic Lateral Sclerosis, Parkinson's Disease, and Schizophrenia); (2) as well as newly identified hallmarks, including Type 2 Diabetes, Cardiovascular diseases (Myocardial Infarction, Heart Disease, Hypertension, Cardiovascular system disease, Vascular Disease), Quantitative trait loci (lipoprotein and body mass index), Cancer (Breast cancer, Colorectal cancer, Prostate cancer, and Lung cancer); (3) and other health conditions; note that cancers reportedly have an inverse relation with AD. We previously suggested that a single gene is associated with multiple neurological diseases predicts complex clinical presentations in people living with AD. Taken together, the genes define AD as a part of age-related comorbidities with shared biological mechanisms and may raise awareness of a
43 44 45 46	Alzheimer's disease is the major cause of dementia. According to the Centers for Disease Control and Prevention (CDC), 5.8 million Americans were living with AD in 2020 (CDC, 2018). Pathological characteristics of AD include diffuse and neuritic plaques characterized

- by amyloid plaques and neurofibrillary tangles (Vaz and Silvestre, 2020; Sherva R, Kowall, 47
- 2022). Despite these pathological characteristics, the brain pathology and progression of AD NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. are clinically heterogeneous and thus, a clinically complex disease (Ferrari and Sorbi, 2021). 48
- 49

- 50 Therefore, AD can be classified as late-onset (LOAD), early-onset (EOAD), and autosomal
- 51 dominant forms of which LOAD is the most frequent.
- 52
- 53 AD is also highly heritable and genetically heterogeneous (Vahdati Nia et al., 2017; Sherva
- 54 R, Kowall, 2022). Linkage analysis, genome-wide association studies and candidate gene
- 55 studies have identified Alzheimer's disease genes (AD genes). Of the 680 AD genes that are
- 56 reported in the Alzgene database (Alzgene.org), 356 genes were found to be associated with
- 57 AD (Vahdati Nia *et al.*, 2017). Four genes are known to cause AD (APP, PSEN1 and PSEN2)
- 58 or to be a risk factor (ApoE4). Based on the AD genes, a previous study identified biological
- 59 Reactome pathways as biological hallmarks (Vahdati Nia *et al.*, 2017). Another important
- 60 finding was that AD genes are associated with 5 neurological diseases, suggesting a single
- 61 gene alteration can be associated with multiple forms of neurological diseases. Here we
- 62 updated and organized the biological hallmarks as well as disease hallmarks. Surprisingly, the
- 63 results suggest more diverse biological hallmarks and include not only neurological diseases
- 64 but also common age-related diseases, which we summarize in this study.

65 66 **Method**

- 67 The method and the AD genes have been described earlier (Vahdati Nia et al., 2017). We
- used 356 AD genes. We used the updated Reactome pathway knowledgebase 2022
- 69 (reactome.org) (Gillespie *et al.*, 2022) and another knowledgebase, GeneAnalytics
- 70 (geneanalytics.genecards.org) (Ben-Ari et al., 2016). The Reactome pathways were set to a
- 71 threshold of p-value ≤ 1.00 E-05. To eliminate redundancies, we categorized the pathways
- 72 into a spectrum ranging from general to specific: general Reactome pathways (general
- hallmarks), more specific pathways (more specific hallmarks), and specific pathways
- 74 (specific hallmarks). For example, a Reactome analysis output in the order from general to
- 75 specific was: Transport of small molecules (as general hallmarks) \rightarrow Plasma lipoprotein
- assembly, remodelling, and clearance (as more specific hallmarks) \rightarrow Plasma lipoprotein clearance (as specific hallmarks). The Reactome results of the top detected hits of AD generation
- clearance (as specific hallmarks). The Reactome results of the top detected hits of AD genes
 include "Plasma lipoprotein clearance" and "Plasma lipoprotein assembly, remodelling, and
- relation relation, reliable relation, relation, relation, relation, relation, relation, reliable relation, relation, relation, relation, relation, rela
- assembly, remodelling, and clearance." Similarly, all the redundant hits are combined and
- 81 summarized.
- 82

83 We identified disease hallmarks, using the knowledgebase, GeneAnalytics

- 84 (geneanalytics.genecards.org) (Ben-Ari et al., 2016) (Accessed on June 28, 2022). The
- 85 knowledgebase uses a total of 74 databases. Of them, we used the results from 72 databases
- 86 (Supplementary table1), excluding the results from 2 databases with potential reliability
- 87 issues (Wikipathways and Wikipedia). The knowledgebase shows a range of p-values. We
- used the disease hits from the high tier with p-value ≤ 0.0001 . The search provided the
- 89 outcome as matched genes and the total genes, the latter of which included those genetically
- 90 associated plus those differentially expressed in the database and thus it covers more genes
- 91 than AD genes. Each disease was ranked based on the score obtained, which is based on (1)
- 92 matched detected gene hits per total genes specific to each condition/quantitative trait locus;
- 93 (2) the quality and the type of differentially expressed genes, genetic association and others;
- 94 more details are described in the GeneAnalytics site above.

9596 Results

- 97
- 98 We updated specific biological pathways, using the latest Reactome knowledgebase analysis
- 99 (Method). A total of 50 updated pathways were identified with a threshold of p-value less

100 than 1.00E-05 (Supplementary Table 2). Table 1 displays the top 10 hits sorted based on their

p-value. We further eliminated the redundancies among the total 50 pathways. This process

102 generated 11 general pathways defined as general biological hallmarks and 20 more specific

103 pathways as defined as more specific biological hallmarks (Method). Of the 11 pathways, 5

- 104 general biological pathways are existing hallmarks reported in the earlier study (Vahdati Nia105 *et al.*, 2017).
- 106

107 Figure 1 summarizes 11 general pathways defined as general biological hallmarks and 20

108 more specific pathways (defined as more specific biological hallmarks). The 11 general

hallmarks (with keywords) are in alphabetical order (asterisks[*] indicate newly identifiedhallmarks):

- 111
- 112 1. Developmental Biology (axon and adipose development)*
- 113 2. Extracellular matrix organization (protein degradation)
- 114 3. Gene expression (RNA polymerase II transcription)*
- 115 4. Hemostasis (platelet regulations)
- 116 5. Immune System (interleukins)
- 117 6. Metabolism (lipoproteins, fat-soluble vitamins, eicosanoids/steroids)
- 118
 7. Metabolism of proteins (Amyloid formation, regulation of IGF-1/Insulin, and small ubiquitin-like modifiers/SUMOs)*
- 120 8. Metabolism of RNA (mitochondrial tRNA and rRNA processing)*
- 121 9. Sensory perception (retinoids)
- 122 10. Signal Transduction (ErbB, NOTCH and p75 NTR death signaling)*
 - 11. Transport of small molecules (lipoproteins)
- 123 124

125 Of the 11 pathway hallmarks, 5 were newly updated hallmarks. "Developmental Biology" include a subcategory in axon and adipose development. Axon development was divided into 126 127 EPH-Ephrin signaling and EPH-ephrin mediated repulsion of cells; the adipose development 128 is from transcriptional regulation of white adipocyte differentiation. "Gene expression" 129 includes RNA Polymerase II Transcription. Although "Metabolism" is an existing hallmark, 130 eicosanoid/steroid is a new subcategory, featuring the synthesis of 5-eicosatetraenoic acids. 131 Notably, "Metabolism of proteins" consists of the pathway directly involved in AD (amyloid 132 formation) and two new pathways, regulation of endocrines and lifespans (regulation of IGF-133 1/insulin) and protein turnover (small ubiquitin-like modifiers/SUMOs). Another hallmark 134 includes a new category "Metabolism of RNA", which is mitochondrial tRNA and rRNA 135 processing in mitochondria. Lastly, "Signal transduction" includes nuclear receptor signaling, 136 including NR1H2 and NR1H3-mediated signaling, ErbB signaling and p75 NTR death 137 signaling, while NOTCH signaling was reported previously (Vahdati Nia et al., 2017).

138

139 We further identified diseases associated with AD genes, using the GeneAnalytics

140 knowledgebase (Method). The knowledgebase ranks the association based on 74 databases by

141 tiers (Method). The detected gene hits of the top 20 diseases are summarized in Table 2 (p-

142 value ≤ 0.0001). Disease hallmarks are summarized in Figure 2. Based on the types of

143 diseases, the AD genes can be classified as: (1) genes specific to neurological diseases; (2)

144 genes more general to common age-related diseases; and (3) genes general to others. The first

- group of diseases was neurological diseases (Alzheimer's disease, General and peripheral
- 146 nervous system disease, Amyotrophic Lateral Sclerosis, Parkinson's Disease, and
- 147 Schizophrenia), which were reported previously (Vahdati Nia *et al.*, 2017). 112 AD genes
- 148 were matched out of 836 AD1 genes that are either genetically associated or differentially
- expressed. AD1 is a specific type of AD caused by mutations in the APP gene, a source of

beta-amyloid. Of a total of 356 AD genes, the gene hits of 112 accounts for 31.4% of AD

151 genes (112 out of 356 AD genes). The second group of diseases are common age-related

diseases. They include type 2 diabetes, cardiovascular diseases (myocardial infarction, heart

153 disease, hypertension, cardiovascular system disease, and vascular disease), cancer (breast 154 cancer, colorectal cancer, prostate cancer, and lung cancer) and others (osteoporosis). Thus,

alterations in AD genes are associated with age-related comorbidities in addition to AD. The

third group introduces other conditions including cystic fibrosis and quantitative trait loci

157 (lipoprotein and body mass index). Surprisingly, cystic fibrosis is included in the disease hit

- 158 by AD genes.
- 159

160 **Discussion**

161

162 This study updated genetic hallmarks for both biological Reactome pathways and those for

163 diseases. We identified 11 general biological pathways, which included 5 existing pathways

and 6 new pathways. The existing biological pathways include: The "immune system"

unfolds pathways involving interleukin-4, 10, and 13 which are involved in the pathology of

166 a wide variety of age-related diseases such as cardiovascular diseases, diabetes and cancers.

167 Similarly, "Metabolism" includes lipoprotein dysregulations relevant to dyslipidemia, and

168 cardiovascular diseases, among others. The previous version of Reactome knowledgebase

169 classified retinoid metabolism as "Metabolism", yet the renewed 2022 version classified it as

170 "Sensory perception". Retinoids or vitamin A are part of fat-soluble vitamins. Thus, we

included "Sensory perception (retinoids)" back to the existing pathway of "Metabolism (fat-soluble vitamins)".

173

174 Of the 6 new biological pathways, "Metabolism of RNA" includes mitochondrial tRNA and 175 rRNA processing in mitochondria. It may be consistent with mitochondrial deletions known 176 to occur during aging, which may cause mitochondrial deficits (Swerdlow *et al.*, 2018; 177 Jang et al., 2018). Another category "gene expression" includes RNA Polymerase II 178 Transcription, which is consistent with common age-related transcriptional changes 179 (Stegeman and Weake, 2018). The category impacts the expression of a wide variety of stress 180 response genes (Stegeman and Weake, 2018). Related to this, stress resistance is a component 181 of life extension in model systems (Johnson et al., 2000; Murakami, 2007; Hamilton and 182 Miller, 2017; Buono and Longo, 2018). Metabolism eicosanoid/steroid is a new subcategory 183 including the synthesis of 5-eicosatetraenoic acids, which is a part of the eicosanoid pathways 184 for lipoxygenase (LOX) and cyclo-oxygenase (COX) pathways among others. The category "Metabolism of proteins," includes the pathway of amyloid formation, regulation of IGF-185 186 1/insulin, and small ubiquitin-like modifiers (SUMOs). Amyloid formation is directly 187 involved in beta-amyloid plaques. The impaired insulin pathway causes diabetes, which is 188 closely related to AD (Moreira 2012; Baglietto-Vargas et al., 2016). SUMOs are involved in 189 protein turnover which is also associated with AD (Hendriks and Vertegaal, 2016). Lastly, "Signal transduction" includes nuclear receptor signaling, including NR1H2 and NR1H3-190 191 mediated signaling, ErbB cancer signaling and p75 NTR death signaling; note that NOTCH 192 signaling was reported previously (Vahdati Nia et al., 2017). NR1H2 and NR1H3 are known 193 as liver-X receptors (LXR), which regulate cholesterol metabolism. They are receptors for 194 their ligands, oxysterols, that are generated by the oxidation of cholesterol through ROS 195 (reactive oxygen species) and other processes (Ma and Nelson ER, 2019). ErbB and p75 NTR

196 are involved in cell survival and death.

197

198 The diseases identified by using AD genes can be categorized into 3 major criteria

199 (neurological diseases, common age-related diseases, and others) and broken down into 6

200 general disease criteria. The first disease criterion is neurological diseases which include 201 Alzheimer's disease, general and peripheral nervous system disease, amyotrophic lateral 202 sclerosis, Parkinson's disease, and schizophrenia. This group has been reported and discussed 203 in the previous study (Vahdati Nia *et al.*, 2017). The study concluded that a single gene 204 alteration may cause multiple neurological diseases. The top hit of the disease in this study 205 was AD1 (Alzheimer's Disease, Familial, 1). Based on affected genes, the efforts on 206 classifying AD have been ongoing and currently classified from AD1 to AD16. AD1 is 207 caused by mutations in the APP genes. AD2 is associated with the ApoE4 allele. AD3 is 208 caused by mutations in PSEN1. AD4 is caused by mutations in the PSEN2 gene. For more 209 details, see the GTR (genetic testing registry) at the NCBI (National Center for 210 Biotechnology Information database) (GTR, 2022, Accessed July 12, 2022). Due to the

- 211 number of AD genes, the list of AD types is expected to be increased in number. The study
- 212 provides a clear example of genetic and phenotypic heterogeneity. The result is consistent 213 with the complex clinical presentations (i.e., clinical heterogeneity) of AD (Ferrari and Sorbi,
- 214 2021).
- 215

216 The second and third disease criteria include common age-related diseases. Age-related

217 diseases are also seen in people as age-related comorbidities, with which two or more

218 diseases commonly occur in a single person. The comorbidities include diabetes (type 2

219 diabetes), cardiovascular diseases (myocardial infarction, heart disease, hypertension, 220 cardiovascular system disease, and vascular disease), cancer (breast cancer, colorectal cancer, 221 prostate cancer, and lung cancer) and others (osteoporosis). It is worth noting that cancers 222 show an inverse relation with AD (Nudelman et al., 2019). The observation is consistent with 223 the previous studies that a major hypertension target, angiotensin-converting enzyme (ACE) 224 is also involved in AD (Le et al., 2020 and 2021). Despite being less defined, AD may be 225 classified as type 3 diabetes, which is a type of diabetes in the brain (Steen et al., 2005; 226 Pilcher, 2006; de la Monte, 2014; Leszek et al., 2017). The vast majority of AD falls into 227 LOAD, whose onset occurs starting at 65 years of age, while age-related diseases occur 228 earlier than that. Although age-related comorbidities are known to be vulnerable to a variety 229 of conditions, for example, COVID-19 (Antos et al., 2021), the straightforward interpretation 230 of the result is that AD genes are associated with AD as well as with common age-related

- diseases.
- 232

233 It is conceptually important that the AD genes define AD as a part of age-related

234 comorbidities with shared biological mechanisms. While the study raises the possibility that

age-related diseases may lead to AD, we are more inclined to the possibility that the shared

biological mechanisms may lead to AD and other age-related comorbidities. We are

beginning to learn that "there is growing evidence that people who adopt healthy lifestyle

- habits...can lower their risk of dementia...which have been shown to prevent cancer,
- diabetes, and heart disease (CDC, 2020)". Moreover, the CDC describes the broad
- 240 neurological behavioral warning signs of Alzheimer's disease, such as memory impairment,
- difficulty in daily tasks, and poor judgement, among others (CDC, 2020). This study further
- suggests that common age-related comorbidities may present early signs when AD genetics isinvolved. Related to this, a wide variety of clinical scenarios may be considered. For
- example, people living with AD gene alterations may have common age-related
- 245 comorbidities and risk of AD development; people living with AD gene alterations may have
- AD with other common age-related comorbidities or people living with AD gene alterations
- 247 may develop neurological and other conditions.
- 248

249 The cure for AD is still unknown. Currently, Aducanumab, a human anti-beta-amyloid 250 antibody, is the only disease-modifying medication approved by FDA (U.S. Food and Drug 251 Administration) (National Institute on Aging, 2021; Alzheimer's Association, 2022). The 252 medication requires assessment of brain beta-amyloid, which uses PET (positron emission 253 tomography) scans or analysis of cerebrospinal fluid. As a clinical approach to AD, we 254 present that age-related comorbidities may provide an early assessment when genetic testing 255 is performed. We also present that the treatment options for age-related comorbidities may be 256 effective when biological mechanisms are considered. Alternatively, the implications from 257 the model systems may be useful for treatment options. Stress resistance confers resistance to 258 multiple forms of stressors, such as pathogens and the toxic beta-amyloid, which is tightly 259 associated with Alzheimer's disease in the model systems (Florez-McClure et al., 2007; 260 Machino et al., 2014). Multiplex stress resistance is a key to understanding the mechanism of 261 extended lifespans and health spans (Murakami et al., 2003; Murakami, 2006). Additionally, 262 stress resistance is tightly associated with life-extending interventions (Murakami, 2006) in 263 which the molecular mechanisms are genetically characterized, for example, the insulin/IGF-264 1 pathways (Murphy and Hu, 2013), and serotonin pathways (Murakami and Murakami, 265 2007), among others; these can be assessed by semi-automated systems (Machino et al., 266 2014). The IGF-1/insulin pathways are a major regulator of lifespans (Finch and Ruvkun, 2001; Kenyon, 2010; Ewald et al., 2018; Zhang et al., 2020) and are involved in age-related 267 268 memory impairment (Murakami et al., 2005). Similarly, the serotonin pathways regulate age-269 related behavioral changes, lifespans and stress resistance (Murakami and Murakami, 2007; 270 Murakami et al., 2008). More details of age-related memory impairment and a related theory 271 (middle-life crisis theory of aging) are described elsewhere (Murakami et al., 2011; 272 Murakami, 2013). Taken together, we suggest that this study of revisiting AD genes provides 273 the strength of treatment options as well as future direction. It will be a powerful way to 274 develop a science-based tool for the long-waited diagnosis, prevention, and treatment options

275 for AD.276

277 Acknowledgement

278

279 This study was devoted to helping my friends and people living with Alzheimer's disease.

280 We thank Student Doctors Timothy Balmorez and Amy Sakazaki and other Murakami lab

281 members for discussion and comments on the manuscript.

282 Figure legend

283

Figure 1. Updated biological hallmarks. We extended the list indicated by Table 1, using
the threshold (p-value < 1.00E-05) and summarized the 11 general biological hallmarks
(circle) and more specific hallmarks (square).

287

Figure 2. Updated disease hallmarks. The diseases listed in Table 2 are organized and

289 grouped into 6 general disease criteria. They are further classified into: (1) neurological

290 diseases (Alzheimer's Disease, Familial, 1, Amyotrophic Lateral Sclerosis 1, Parkinson

291 Disease, Late-Onset, Schizophrenia, Peripheral Nervous System Disease, Nervous System

292 Disease, others); (2) common age-related diseases (Diabetes, Cardiovascular Disease, Cancer

and Osteoporosis); and (3) other diseases (Quantitative Trait Loci and Cystic fibrosis). Note

that cancers are reported to show an inverse relationship with AD genes (indicated by astericks)

asterisks).

296 Table

297

298 **Table 1. Updated top 10 Reactome pathways.** The Reactome analysis updated the

299 biological pathways that we define as biological hallmarks (Accessed on June 28, 2022).

300 FDR (False detection rate).

3<u>01</u>

General Reactome pathways	More specific pathways	Specific Pathway	p-value	FDR	HitGenes
Metabolism of RNA	tRNA processing	tRNA processing in the mitochondrion	1.11E-16	1.05E-13	MT-TQ,MT-ND6,MT-ND4L,MT- ND4,MT-TT,MT-TR,MT- ND2,MT-ND3,MT-ND1,MT- TH,MT-CO2,MT-TG,MT- CO3,MT-TS2,MT-ATP6,MT- ATP8,MT-RNR1,MT-CYB
Transport of small molecules	Plasma lipoprotein assembly, remodeling, and clearance	Plasma lipoprotein assembly, remodeling, and clearance	3.33E-16	1.57E-13	LIPA,LIPC,SOAT1,CETP,APOE, A2M,ABCA1,VLDLR,LDLR,NR H2,ABCG1,LPL,ALB,APOA1,AF OA4,APOA5,NPC1,NPC2,APOC ,APOC2,APOC1
Metabolism of RNA	rRNA processing	rRNA processing in the mitochondrion	6.00E-15	1.88E-12	MT-ND4L,MT-ND4,MT-TT,MT- TR,MT-ND2,MT-ND3,MT- ND1,MT-TH,MT-CO2,MT- TG,MT-CO3,MT-TS2,MT- ATP6,MT-ATP8,MT-RNR1,MT- CYB
Immune system	Signaling by interneukins	Interleukin-4 and Interleukin-13 signaling	1.94E-12	4.55E-10	ICAM1,TP53,MAOA,PIK3R1,HN OX1,CD36,IL10,IL18,IL1A,IL1B PTGS2,ALOX5,F13A1,TNF,TGF B1,POU2F1,IL6,IL8,MMP1,MMF 3,CCL2
Transport of small molecules	Plasma lipoprotein assembly, remodeling, and clearance	Plasma lipoprotein clearance	8.06E-11	1.52E-08	LIPA,LIPC,SOAT1,APOE,VLDL R,LDLR,NR1H2,APOA1,NPC1,N PC2,APOC4,APOC1
Immune system	Signaling by interleukins	Interleukin-10 signaling	3.56E-10	5.60E-08	IL1RN,ICAM1,CCR2,IL10,IL18,I L1A,IL1B,PTGS2,TNF,IL6,IL8,C CL3,CCL2
Sensory perception	Visual phototransducti on	Retinoid metabolism and transport	2.00E-09	2.68E-07	LRAT,HSPG2,APOE,LDLR,LPL, APOA1,APOA4,LRP1,LRP2,LRP 8,TTR,APOC2
Metabolism of proteins	Amyloid fiber formation	Amyloid fiber formation	2.98E-09	3.48E-07	APP,HSPG2,APH1A,NCSTN,AP H1B,APOE,PSENEN,BACE1,CS T3,ADAM10,APOA1,APOA4,TT R,SNCA,SORL1

Transport of small molecules	Metabolism of vitamins and cofactors	Metabolism of fat-soluble vitamins	5.19E-09	5.40E-07	LRAT,HSPG2,APOE,LDLR,LPL, APOA1,APOA4,LRP1,LRP2,LRP 8,TTR,APOC2
Immune system	Signaling by Interleukins	Signaling by Interleukins	1.65E-08	1.46E-06	APP,IL1RN,ICAM1,MEF2A,TP5, ,MAOA,PIK3R1,HMOX1,CD36,C CR2,IL10,GSTO1,IL18,GAB2,IL A,IL1B,PTGS2,ALOX5,IL33,F13 A1,TNF,AGER,TGFB1,POU2F1, L6,IL8,MMP1,MMP3,LCK,SOS2 CCL3,CCL2,S100B,SOD2

Table 2. Diverse disease hallmarks are associated with AD genes. The top 20 diseases in
the high tier (p-value equal or less than 0.0001) are listed. The AD gene sets in Table 1 are
used to identify diseases using all 356 AD genes (Vahdati Nia *et al.*, 2017) and the web-based
search using GeneAnalytics (Accessed on June 28, 2022). *, The number of AD gene hits
(total genes classified in each group of the health conditions/Loci).

General criteria	Health conditions/loci	# Matched gene hits (Total genes)*
Neurological	Alzheimer Disease, Familial, 1	112 (836)
Neurological	Nervous System Disease	91 (897)
Diabetes	Type 2 Diabetes Mellitus	84 (555)
Cardiovascular	Myocardial Infarction	68 (302)
QTL*	Body Mass Index Quantitative Trait Locus 11	76 (819)
Cancer	Breast Cancer	73 (1447)
Cardiovascular	Heart Disease	61 (366)
Cardiovascular	Hypertension, Essential	59 (457)
Cancer	Colorectal Cancer	70 (1492)
Neurological	Amyotrophic Lateral Sclerosis 1	55 (579)
Cardiovascular	Cardiovascular System Disease	51 (192)
Neurological	Parkinson Disease, Late-Onset	52 (387)
Other	Lipoprotein Quantitative Trait Locus	49 (248)
Cardiovascular	Vascular Disease	44 (149)
Neurological	Schizophrenia	48 (464)
Neurological	Peripheral Nervous System Disease	46 (369)
Cancer	Prostate Cancer	56 (1121)
Other	Osteoporosis	44 (308)
Cancer	Lung Cancer	50 (1218)
Other	Cystic Fibrosis	40 (333)

314 **References:**

315

- 316 Alzheimer's Association (2022). Aducanumab Approved for Treatment of Alzheimer's
- 317 Disease. Retrieved July 12, 2022 from https://www.alz.org/alzheimers-
- 318 dementia/treatments/aducanumab
- 319
- Antos A, Kwong ML, Balmorez T, Villanueva A, Murakami S. Unusually High Risks of
- 321 COVID-19 Mortality with Age-Related Comorbidities: An Adjusted Meta-Analysis Method
- 322 to Improve the Risk Assessment of Mortality Using the Comorbid Mortality Data. Infect Dis
- Rep. 2021 Aug 8;13(3):700-711. doi: 10.3390/idr13030065. PMID: 34449622; PMCID:
 PMC8395741.
- 324 325
- Ben-Ari Fuchs S, Lieder I, Stelzer G, Mazor Y, Buzhor E, Kaplan S, Bogoch Y, Plaschkes I,
 Shitrit A, Rappaport N, Kohn A, Edgar R, Shenhav L, Safran M, Lancet D, Guan-Golan Y,
 Warshawsky D, Shtrichman R. GeneAnalytics: An Integrative Gene Set Analysis Tool for
- 329 Next Generation Sequencing, RNAseq and Microarray Data. OMICS. 2016 Mar;20(3):139-
- 330 51. doi: 10.1089/omi.2015.0168. PMID: 26983021; PMCID: PMC4799705.
- 331
- Buono R, Longo VD. Starvation, Stress Resistance, and Cancer. Trends Endocrinol Metab.
- 333 2018 Apr;29(4):271-280. doi: 10.1016/j.tem.2018.01.008. Epub 2018 Feb 17. PMID:
 334 29463451; PMCID: PMC7477630.
- 334 335
- 336 Centers for Disease Control and Prevention (October 26, 2020) Alzheimer's Disease and
- 337 Related Dementias. Retrieved July 12, 2022 from
- 338 https://www.cdc.gov/aging/aginginfo/alzheimers.htm.
- 339
- de la Monte SM. Type 3 diabetes is sporadic Alzheimer's disease: mini-review. Eur
 Neuropsychopharmacol. 2014 Dec;24(12):1954-60. doi: 10.1016/j.euroneuro.2014.06.008.
- 342 Epub 2014 Jun 28. PMID: 25088942; PMCID: PMC4444430.
- 343
- Ewald CY, Castillo-Quan JI, Blackwell TK. Untangling Longevity, Dauer, and Healthspan in
 Caenorhabditis elegans Insulin/IGF-1-Signalling. Gerontology. 2018;64(1):96-104. doi:
 10.1159/000480504. Epub 2017 Sep 22. PMID: 28934747; PMCID: PMC5828946.
- 347
- Ferrari C, Sorbi S. The complexity of Alzheimer's disease: an evolving puzzle. Physiol Rev.
 2021 Jul 1;101(3):1047-1081. doi: 10.1152/physrev.00015.2020. Epub 2021 Jan 21. PMID:
 33475022.
- 351
- 352 Gillespie M, Jassal B, Stephan R, Milacic M, Rothfels K, Senff-Ribeiro A, Griss J, Sevilla C,
- 353 Matthews L, Gong C, Deng C, Varusai T, Ragueneau E, Haider Y, May B, Shamovsky V,
- Weiser J, Brunson T, Sanati N, Beckman L, Shao X, Fabregat A, Sidiropoulos K, Murillo J,
- Viteri G, Cook J, Shorser S, Bader G, Demir E, Sander C, Haw R, Wu G, Stein L, Hermjakob
- H, D'Eustachio P. The reactome pathway knowledgebase 2022. Nucleic Acids Res. 2022 Jan 7.50(D1):D(27 D(02) dai: 10.1002/mar/glash1028_DMD: 24788842; DMCID:
- 357 7;50(D1):D687-D692. doi: 10.1093/nar/gkab1028. PMID: 34788843; PMCID:
 358 PMC8689983.
- 358 359
- 360 Hamilton KL, Miller BF. What is the evidence for stress resistance and slowed aging? Exp
- 361 Gerontol. 2016 Sep;82:67-72. doi: 10.1016/j.exger.2016.06.001. Epub 2016 Jun 4. PMID:
 362 27268049.
- 363

364	
365	Finch CE, Ruvkun G. The genetics of aging. Annu Rev Genomics Hum Genet. 2001;2:435-
366	62. doi: 10.1146/annurev.genom.2.1.435. PMID: 11701657.
367	
368	Florez-McClure ML, Hohsfield LA, Fonte G, Bealor MT, Link CD. Decreased insulin-
369	receptor signaling promotes the autophagic degradation of beta-amyloid peptide in C.
370	elegans. Autophagy. 2007 Nov-Dec;3(6):569-80. doi: 10.4161/auto.4776. Epub 2007 Jul 20.
371	Erratum in: Autophagy. 2007 Nov-Dec,5(0):507-80. doi: 10.4101/add.4770. Epub 2007 Jul 20.
	Enatum m. Autophagy. 2009 Jan 1,5(1).152-5. FWID. 17075890.
372	
373	Genetic Testing Registry (2022). National Center for Biotechnology Information. Alzheimer
374	Disease. Retrieved July 12, 2022 from
375	https://www.ncbi.nlm.nih.gov/gtr/conditions/C0002395/
376	
377	Hendriks IA, Vertegaal AC. A comprehensive compilation of SUMO proteomics. Nat Rev
378	Mol Cell Biol. 2016 Sep;17(9):581-95. doi: 10.1038/nrm.2016.81. Epub 2016 Jul 20. PMID:
379	27435506.
380	
381	Johnson TE, Cypser J, de Castro E, de Castro S, Henderson S, Murakami S, Rikke B,
382	Tedesco P, Link C. Gerontogenes mediate health and longevity in nematodes through
383	
	increasing resistance to environmental toxins and stressors. Exp Gerontol. 2000 Sep;35(6-
384	7):687-94. doi: 10.1016/s0531-5565(00)00138-8. PMID: 11053658.
385	
386	Kenyon CJ. The genetics of ageing. Nature. 2010 Mar 25;464(7288):504-12. doi:
387	10.1038/nature08980. Erratum in: Nature. 2010 Sep 30;467(7315):622. PMID: 20336132.
388	
389	Le D, Crouch N, Villanueva A, Ta P, Dmitriyev R, et al. 2020. Evidence-Based Genetics and
390	Identification of Key Human Alzheimer's Disease Alleles with Co-morbidities. J Neurol Exp
391	Neurosci 6(1): 20-24. doi: 10.17756/jnen.2020-069.
392	() · · · · · · · · · · · · · · · · · · ·
393	Le D, Brown L, Malik K, Murakami S. Two Opposing Functions of Angiotensin-Converting
394	Enzyme (ACE) That Links Hypertension, Dementia, and Aging. Int J Mol Sci. 2021 Dec
395	7;22(24):13178. doi: 10.3390/ijms222413178. PMID: 34947975; PMCID: PMC8707689.
	7,22(24).15178. doi: 10.5590/1jiiis2222415178. FivilD. 54947975, FiviCiD. FiviCo707089.
396	
397	Leszek J, Trypka E, Tarasov VV, Ashraf GM, Aliev G. Type 3 Diabetes Mellitus: A Novel
398	Implication of Alzheimers Disease. Curr Top Med Chem. 2017;17(12):1331-1335. doi:
399	10.2174/1568026617666170103163403. PMID: 28049395.
400	
401	Ma L, Nelson ER. Oxysterols and nuclear receptors. Mol Cell Endocrinol. 2019 Mar
402	15;484:42-51. doi: 10.1016/j.mce.2019.01.016. Epub 2019 Jan 18. PMID: 30660701.
403	
404	Machino K, Link CD, Wang S, Murakami H, Murakami S. A semi-automated motion-
405	tracking analysis of locomotion speed in the C. elegans transgenics overexpressing beta-
406	amyloid in neurons. Front Genet. 2014 Jul 4;5:202. doi: 10.3389/fgene.2014.00202. PMID:
407	25071831; PMCID: PMC4082091.
408	25071051, 11010, 110101002071.
408	Murakami S. Strass resistance in long lived mouse models. Ever Corontal 2006
	Murakami S. Stress resistance in long-lived mouse models. Exp Gerontol. 2006
410	Oct;41(10):1014-9. doi: 10.1016/j.exger.2006.06.061. Epub 2006 Sep 7. PMID: 16962277.
411	

412 Murakami S. Caenorhabditis elegans as a model system to study aging of learning and

- 413 memory. Mol Neurobiol. 2007 Feb;35(1):85-94. doi: 10.1007/BF02700625. PMID:
 414 17519507.
- 415

416 Murakami, S. (2013) Age-dependent modulation of learning and memory in C. elegans. In

- 417 Menzel R and Benjamin P.R. (Eds.) Invertebrate Learning and Memory; Handbook of
- 418 Behavioral Neuroscience. Elsevier/Academic Press. Ch.12, Pages 140-150. Book Chapter.
- 419
- 420 Murakami H, Bessinger K, Hellmann J, Murakami S. Aging-dependent and -independent
- 421 modulation of associative learning behavior by insulin/insulin-like growth factor-1 signal in
 422 Caenorhabditis elegans. J Neurosci. 2005 Nov 23;25(47):10894-904. doi:
- 423 10.1523/JNEUROSCI.3600-04.2005. PMID: 16306402; PMCID: PMC6725869.
- 424
- 425 Murakami H, Bessinger K, Hellmann J, Murakami S. Manipulation of serotonin signal
- 426 suppresses early phase of behavioral aging in Caenorhabditis elegans. Neurobiol Aging. 2008
- 427 Jul;29(7):1093-100. doi: 10.1016/j.neurobiolaging.2007.01.013. Epub 2007 Mar 1. PMID:
 428 17336425.
- 429
- 430 Murakami, S., Cabana, K., Anderson, D. (2011) Current advances in the study of oxidative
- 431 stress and age-related memory impairment in C. elegans. In Farooqui, T. Farooqui, A. (Ed.)
 432 Molecular aspects of oxidative stress on cell signaling in vertebrates and invertebrates, John
- 433 Wiley & Sons, Hoboken, NJ. Ch 25, Pages 347-360. Book Chapter.
- 434
- 435 Murakami H, Murakami S. Serotonin receptors antagonistically modulate Caenorhabditis
- 436 elegans longevity. Aging Cell. 2007 Aug;6(4):483-8. doi: 10.1111/j.1474-
- 437 9726.2007.00303.x. Epub 2007 Jun 8. PMID: 17559503.
- 438

Murakami S, Salmon A, Miller RA. Multiplex stress resistance in cells from long-lived dwarf
mice. FASEB J. 2003 Aug;17(11):1565-6. doi: 10.1096/fj.02-1092fje. Epub 2003 Jun 3.
PMID: 12824282.

442

443 Murphy CT, Hu PJ. Insulin/insulin-like growth factor signaling in C. elegans. WormBook.
444 2013 Dec 26:1-43. doi: 10.1895/wormbook.1.164.1. PMID: 24395814; PMCID:

- 445 PMC4780952.
- 446
- 447 National Institute on Aging (2021). How Is Alzheimer's Disease Treated? Retrieved July 12,
 448 2022 from https://www.nia.nih.gov/health/how-alzheimers-disease-treated
- 449
- 450 Nudelman KNH, McDonald BC, Lahiri DK, Saykin AJ. Biological Hallmarks of Cancer in
 451 Alzheimer's Disease. Mol Neurobiol. 2019 Oct;56(10):7173-7187. doi: 10.1007/s12035-019-
- 452 1591-5. Epub 2019 Apr 16. PMID: 30993533; PMCID: PMC6728183.
- 453
- 454 Pilcher H. Alzheimer's disease could be "type 3 diabetes". Lancet Neurol. 2006
- 455 May;5(5):388-9. doi: 10.1016/s1474-4422(06)70434-3. PMID: 16639835.
- 456
- 457 Sherva R, Kowall NW (May 19, 2022) Genetics of Alzheimer disease. In: UpToDate, Steven
- 457 Sherva R, Rowan IVV (Way 19, 2022) Scherces of Alzheiner disease. In: OptoDate, Steven
 458 T DeKosky ST, Raby BA, Wilterdink JL (Eds), UpToDate, Waltham, MA. Retrieved July 2,
 459 2022.
- 460

- 461 Steen E, Terry BM, Rivera EJ, Cannon JL, Neely TR, Tavares R, Xu XJ, Wands JR, de la
- 462 Monte SM. Impaired insulin and insulin-like growth factor expression and signaling
- 463 mechanisms in Alzheimer's disease--is this type 3 diabetes? J Alzheimers Dis. 2005 464 Fab:7(1):63 80 doi: 10.3233/ind.2005.7107_PMID: 15750215
- 464 Feb;7(1):63-80. doi: 10.3233/jad-2005-7107. PMID: 15750215.
- 465466 Swerdlow RH. Mitochondria and Mitochondrial Cascades in Alzheimer's Disease. J
- 400 Swerdlow KH. Whochondria and Whochondria Cascades in Alzheimer's Disease. J 467 Alzheimers Dis. 2018;62(3):1403-1416. doi: 10.3233/JAD-170585. PMID: 29036828;
- 468 PMCID: PMC5869994.
- 469
- 470 Stegeman R, Weake VM. Transcriptional Signatures of Aging. J Mol Biol. 2017 Aug
- 471 4;429(16):2427-2437. doi: 10.1016/j.jmb.2017.06.019. Epub 2017 Jul 3. PMID: 28684248;
 472 PMCID: PMC5662117.
- 473
- 474 Vahdati Nia B, Kang C, Tran MG, Lee D, Murakami S. Meta Analysis of Human AlzGene
- 475 Database: Benefits and Limitations of Using *C. elegans* for the Study of Alzheimer's Disease
- 476 and Co-morbid Conditions. Front Genet. 2017 May 12;8:55. doi: 10.3389/fgene.2017.00055.
- 477 PMID: 28553317; PMCID: PMC5427079.
- 478
- 479 Vaz M, Silvestre S. Alzheimer's disease: Recent treatment strategies. Eur J Pharmacol. 2020
- 480 Nov 15;887:173554. doi: 10.1016/j.ejphar.2020.173554. Epub 2020 Sep 15. PMID:
 481 32941929.
- 482
- 483 Zhang ZD, Milman S, Lin JR, Wierbowski S, Yu H, Barzilai N, Gorbunova V, Ladiges WC,
- 484 Niedernhofer LJ, Suh Y, Robbins PD, Vijg J. Genetics of extreme human longevity to guide
- 485 drug discovery for healthy ageing. Nat Metab. 2020 Aug;2(8):663-672. doi: 10.1038/s42255-
- 486 020-0247-0. Epub 2020 Jul 27. PMID: 32719537; PMCID: PMC7912776.



Figure 1



Figure 2